{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:44:47Z","timestamp":1784907887842,"version":"3.55.0"},"reference-count":67,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Novartis Services Inc."}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>ATP-competitive tyrosine kinase inhibitors (TKIs) are the current standard of care for patients with chronic phase-chronic myeloid leukemia (CP-CML) in the first-line and second-line (2 L) setting. Treatment after 2 L is not clearly established.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The objective of this study was to summarize the available evidence to compare the efficacy and safety of interventions in the treatment of CP-CML patients who had received \u2a7e2 prior TKIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>A systematic literature review was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data source and methods:<\/jats:title>\n                    <jats:p>A systematic literature review (SLR) of studies published until May 2021, reporting clinical outcomes in adult patients with CP-CML who had received\u2009\u2a7e\u20092 prior TKIs was performed. Studies were identified through the database searches via Ovid platform (Embase, MEDLINE Epub Ahead of Print, In-Process and Other Non-Indexed Citations, and Cochrane Central Register of Controlled Trials), the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), bibliographic search of relevant reviews, and proceedings from the previous 3 years of the key conferences in the field of oncology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Our search identified 38 relevant studies. Among the identified studies of the current third-line treatments, the major molecular response (MMR) rate for ponatinib was 19.0\u201366.7%, 23.3\u201325.5% for asciminib, 19.2% for omacetaxine, and 13.2% for bosutinib at 6 months. The complete cytogenetic response (CCyR) rate was 21.4\u201364.8% for ponatinib, 38.7\u201340.8% for asciminib, 18\u201324.2% for bosutinib, and 16.1% for omacetaxine at 6 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The findings from current SLR demonstrated the lack of data for patients with CML treated with \u2a7e2 TKIs. TKIs such as asciminib, ponatinib, and bosutinib are valid options for those patients. Further research is needed to identify the best treatment option for patients with CML receiving later lines of therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406207221150305","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T02:43:54Z","timestamp":1702608234000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with \u2a7e2 tyrosine kinase inhibitors: a systematic literature review"],"prefix":"10.1177","volume":"14","author":[{"given":"Ehab","family":"Atallah","sequence":"first","affiliation":[{"name":"Cancer Center \u2013 Froedtert Hospital, Medical College of Wisconsin, Milwaukee, WI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lovneet","family":"Saini","sequence":"additional","affiliation":[{"name":"Novartis Healthcare Pvt. Ltd., Hyderabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Maegawa","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanvi","family":"Rajput","sequence":"additional","affiliation":[{"name":"Novartis Healthcare Pvt. Ltd., Hyderabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3664-0187","authenticated-orcid":false,"given":"Regina","family":"Corbin","sequence":"additional","affiliation":[{"name":"Novartis Services Inc, One Health Plaza, East Hanover, NJ 07936-1080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Viana","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,12,14]]},"reference":[{"key":"bibr1-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01055-9"},{"key":"bibr2-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61165-9"},{"key":"bibr3-20406207221150305","unstructured":"American Cancer Society. Key statistics for chronic myeloid leukemia, https:\/\/www.cancer.org\/cancer\/chronic-myeloid-leukemia\/about\/statistics.html (2018, accessed 16 August 2021)."},{"key":"bibr4-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-64263-5_2"},{"key":"bibr5-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx219"},{"key":"bibr6-20406207221150305","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines in oncology \u2013 chronic myeloid leukemia (version 3.2021 \u2013 January 13 2021), https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf (accessed 11 March 2021)."},{"key":"bibr7-20406207221150305","unstructured":"Surveillance Epidemiology End Results Program. Cancer stat facts: leukemia \u2013 chronic myeloid leukemia (CML), https:\/\/seer.cancer.gov\/statfacts\/html\/cmyl.html (2021, accessed 16 August 2021)."},{"key":"bibr8-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2314-2"},{"key":"bibr9-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2"},{"key":"bibr10-20406207221150305","unstructured":"European Medicines Agency. Bosutinib-summary of product characteristics, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bosulif-epar-product-information_en.pdf (2013, accessed 28 September 2021)."},{"key":"bibr11-20406207221150305","unstructured":"US Food and Drug Administration. Bosutinib FDA approval, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/203341s020lbl.pdf (2012, accessed 28 September 2021)."},{"key":"bibr12-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2009.06.005"},{"key":"bibr13-20406207221150305","unstructured":"National Institute of Health Care Excellence. Single technology appraisal: user guide for company evidence submission template, https:\/\/www.nice.org.uk\/process\/pmg24\/resources\/single-technology-appraisal-and-highly-specialised-technologies-evaluation-user-guide-for-company-evidence-submission-template-pdf-72286715419333"},{"key":"bibr14-20406207221150305","unstructured":"Cancer Network. FDA Grants orphan drug designation to HQP1351 for chronic myeloid leukemia, https:\/\/www.cancernetwork.com\/view\/fda-grants-orphan-drug-designation-hqp1351-chronic-myeloid-leukemia"},{"key":"bibr15-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1177\/2040620717719851"},{"key":"bibr16-20406207221150305","unstructured":"National Institute of Health Care Excellence. Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia \u2013 Technology appraisal guidance [TA451], https:\/\/www.nice.org.uk\/guidance\/ta451\/resources\/ponatinib-for-treating-chronic-myeloid-leukaemia-and-acute-lymphoblastic-leukaemia-pdf-82604840051653"},{"key":"bibr17-20406207221150305","unstructured":"National Institute of Health Care Excellence. Bosutinib for previously treated chronic myeloid leukaemia \u2013 single technology appraisal [ID495], https:\/\/www.nice.org.uk\/guidance\/ta576\/documents\/final-matrix"},{"key":"bibr18-20406207221150305","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/HS9.0000000000000107","volume":"2","author":"Turkina A","year":"2018","journal-title":"Hemasphere"},{"key":"bibr19-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-221531"},{"key":"bibr20-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902328"},{"key":"bibr21-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390120"},{"key":"bibr22-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.2017.1385193"},{"key":"bibr23-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"bibr24-20406207221150305","unstructured":"Wells GS, O\u2019Connell D, Peterson J, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp (2013, accessed 1 October 2016)."},{"key":"bibr25-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-143816"},{"key":"bibr26-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.7000"},{"key":"bibr27-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.7000"},{"key":"bibr28-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-415307"},{"key":"bibr29-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2018.08.006"},{"key":"bibr30-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0915-9"},{"key":"bibr31-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2851"},{"key":"bibr32-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-138690"},{"key":"bibr33-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000268"},{"key":"bibr34-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04507-x"},{"key":"bibr35-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23408"},{"key":"bibr36-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-142142"},{"key":"bibr37-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124295"},{"key":"bibr38-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.110"},{"key":"bibr39-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1159\/000495335"},{"key":"bibr40-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119914"},{"key":"bibr41-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205127"},{"key":"bibr42-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2238-9"},{"key":"bibr43-20406207221150305","author":"Khan M","year":"2017","journal-title":"American Society of Hematology Annual Meeting and Exposition 2017"},{"key":"bibr44-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-142954"},{"key":"bibr45-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3507-2"},{"key":"bibr46-20406207221150305","volume":"2018","author":"Tiribelli M","year":"2018","journal-title":"American Society of Hematology Annual Meeting and Exposition"},{"key":"bibr47-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2239-8"},{"key":"bibr48-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-121784"},{"key":"bibr49-20406207221150305","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.064337"},{"key":"bibr50-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-291922"},{"key":"bibr51-20406207221150305","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2015(08)04"},{"key":"bibr52-20406207221150305","author":"Garcia-Gutierrez JV","year":"2012","journal-title":"American Society of Hematology"},{"key":"bibr53-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-141077"},{"key":"bibr54-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24536"},{"key":"bibr55-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-142142"},{"key":"bibr56-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306494"},{"key":"bibr57-20406207221150305","first-page":"1617","volume":"130","author":"Hochhaus A","year":"2017","journal-title":"Blood"},{"key":"bibr58-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(20)30830-2"},{"key":"bibr59-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1179\/1607845413Y.0000000100"},{"key":"bibr60-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126098"},{"key":"bibr61-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-739086"},{"key":"bibr62-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25527"},{"key":"bibr63-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.07.004"},{"key":"bibr64-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0842-9"},{"key":"bibr65-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.104"},{"key":"bibr66-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009984"},{"key":"bibr67-20406207221150305","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7004"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207221150305","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207221150305","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207221150305","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:16:29Z","timestamp":1777590989000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207221150305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":67,"alternative-id":["10.1177\/20406207221150305"],"URL":"https:\/\/doi.org\/10.1177\/20406207221150305","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"article-number":"20406207221150305"}}